World Gastric Cancer Market Undergoes Gradual Changes, According to GBI Research Study Available at MarketPublishers.com12 May 2016 • by Natalie Aster
LONDON – Due to its indolent nature, gastric cancer is still one of the prevalent causes of cancer related mortality in people worldwide; it is the 5th most common cancer worldwide. This poor outlook, especially for patients in advanced stages of the disease, has generated an urgent need for enhanced treatment options.
From pole to pole, the gastric cancer market is making a gradual turn, with a focus shifting from generic chemotherapy drug regimens to complex treatment algorithms on the basis of molecularly targeted therapies. In the recent past, the market has seen efficacious therapies like Cyramza be approved by the FDA; however, this is only of benefit to a small number of patients. As the comprehension of disease pathophysiology surges, novel targets need to be detected and converted into more advanced therapeutic options. Today’s pipeline holds out a hope, as it demonstrates a gradual transition from generic cytotoxic drug therapies to more versatile targeted cancer therapies.
Topical study “Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs” elaborated by GBI Research carefully examines the marketplace on a global level.
The report offers a true understanding of the actual clinical and commercial panorama by inspecting the pathogenesis, diagnosis and prognosis of gastric carcinoma, and the therapy options available at each diagnosis stage, alongside comparing the currently marketed therapies. The study describes the structure of the market with respect to leading therapies for each patient subgroup alongside their status, clinical and commercial alike. It highlights unmet needs in the present-day marketplace. The publication gives an overview of the pipeline and stratifies pipeline therapies based on development stage, type of molecule, and molecular target. It evaluates and ranks the clinical potential of first-in-class products, with promising early-stage targets being further examines in more detail. The report identifies the commercial opportunities in the gastric carcinoma deals landscape by canvassing the co-development and licensing deal trends and listing the gastric cancer therapies that may be potential areas for investment.
More reports by the publisher can be found at GBI Research page.